Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia.

导出 LinkOut

翻译打印收藏纠错

作者： Ai Leng,Khoo ^[1] ; Ying Jiao,Zhao ^[1] ; Monica,Teng ^[1] ; Ding,Ying ^[2] ; Jing,Jin ^[3] ; Yen Lin,Chee ^[4] ; Li Mei,Poon ^[4] ; Siew Eng,Lim ^[4] ; Liang Piu,Koh ^[4] ; Wee Joo,Chng ^[4] ; Boon Peng,Lim ^[1] ; Li Yang,Hsu ^[5] ; Louis Yi Ann,Chai ^[6]

作者单位： Pharmacy and Therapeutics Office, Group Health Informatics, National Healthcare Group, Singapore. ^[1] Department of Infectious Diseases, Institute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, Singapore. ^[2] Children's Minnesota Research Institute, Children's Hospitals and Clinics of Minnesota, Minneapolis-Saint Paul, MN, USA. ^[3] Department of Haematology-Oncology, National University Cancer Institute, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. ^[4] Department of Infectious Diseases, Institute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. ^[5] Department of Haematology-Oncology, National University Cancer Institute, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Division of Infectious Diseases, University Medicine Cluster, National University Health System, Singapore. Electronic address: chailouis@hotmail.com. ^[6]

关键词 Antimicrobial Carbapenem Chemotherapy Febrile neutropenia Immunocompromised Piperacillin/tazobactam